Gsk Buy Or Sell Apr 2026

Despite strong fundamentals, many analysts recommend caution in the immediate term: GSK (GSK) Earnings Expected to Grow: Should You Buy?

Management has reaffirmed its 2026 outlook, expecting core EPS growth of 7% to 9%. Key growth drivers include Arexvy (RSV vaccine) and expansion into specialty medicines like HIV and Oncology. gsk buy or sell

For investors with a longer time horizon, GSK presents a compelling "Buy" narrative centered on its successful pivot to a high-margin, pure-play pharmaceutical company: Despite strong fundamentals